InMed Pharmaceuticals Advances Oral Candidate For Alzheimer's Disease, Stock Surges On Tuesday

On Tuesday, InMed Pharmaceuticals Inc. INM confirmed INM-901 as an oral formulation that will be utilized in its development programs for Alzheimer's disease. Recent preclinical studies have demonstrated that INM-901, a proprietary small molecule drug candidate, can be administered orally and achieve therapeutic levels in the brain comparable to those obtained through the intraperitoneal or abdominal cavity (IP) injection, which is a common route of administration for preclinical investigation of neurodegen ...